4538
Fuso Pharmaceutical Industries,Ltd.
扶桑薬品工業
- Industry
- Pharmaceutical
- Market
- Prime
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Non-consolidated
Key metrics
Revenue(million JPY)
Mar 2021
49,251
Mar 2022
49,632
Mar 2023
51,015
Mar 2024
55,407
Mar 2025
60,563
Operating profit(million JPY)
Mar 2021
2,351
Mar 2022
1,924
Mar 2023
2,206
Mar 2024
1,964
Mar 2025
4,131
Operating profit margin(%)
Mar 2021
4.77
Mar 2022
3.88
Mar 2023
4.32
Mar 2024
3.54
Mar 2025
6.82
Profit before tax(million JPY)
Mar 2021
2,345
Mar 2022
1,911
Mar 2023
2,205
Mar 2024
1,767
Mar 2025
-4,970
Profit(million JPY)
Mar 2021
1,607
Mar 2022
1,483
Mar 2023
1,605
Mar 2024
1,377
Mar 2025
-3,288
Total assets(million JPY)
Mar 2021
69,876
Mar 2022
69,334
Mar 2023
72,466
Mar 2024
75,802
Mar 2025
81,729
Cash and cash equivalents(million JPY)
Mar 2021
7,074
Mar 2022
7,347
Mar 2023
8,014
Mar 2024
5,120
Mar 2025
6,264
Cash flows from operating activities(million JPY)
Mar 2021
3,230
Mar 2022
3,498
Mar 2023
2,853
Mar 2024
627
Mar 2025
-3,305
Cash flows from investing activities(million JPY)
Mar 2021
-978
Mar 2022
-1,553
Mar 2023
-1,373
Mar 2024
-3,536
Mar 2025
-3,168
Cash flows from financing activities(million JPY)
Mar 2021
-2,446
Mar 2022
-1,671
Mar 2023
-813
Mar 2024
14
Mar 2025
7,618
Return on equity(%)
Mar 2021
4.9
Mar 2022
4.3
Mar 2023
4.6
Mar 2024
3.8
Mar 2025
-9.4
Equity ratio(%)
Mar 2021
48.2
Mar 2022
49.8
Mar 2023
49.2
Mar 2024
48.4
Mar 2025
40.4
Earnings per share(JPY per share)
Mar 2021
183.18
Mar 2022
169.09
Mar 2023
183.07
Mar 2024
159.98
Mar 2025
-384.95
Net assets per share(JPY per share)
Mar 2021
3,839.54
Mar 2022
3,936.7
Mar 2023
4,064.76
Mar 2024
4,290.55
Mar 2025
3,869.1
Dividend per share(JPY per share)
Mar 2021
60
Mar 2022
60
Mar 2023
70
Mar 2024
70
Mar 2025
82
Payout ratio(%)
Mar 2021
32.75
Mar 2022
35.48
Mar 2023
38.24
Mar 2024
43.76
Mar 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.